
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>AGA Clinical Practice Update on Management of Gastric Polyps: Expert Review</title>
<style>

<style>
/* ===== GENERAL LAYOUT ===== */
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #eef2ff, #fafafa);
    color: #2c2c2c;
    padding: 30px;
    margin: 0;
}

/* Centered mindmap container */
.mindmap {
    max-width: 800px;
    margin: auto;
    font-size: 20px;
    line-height: 1.7;
}

/* ===== LISTS ===== */
.mindmap ul {
    margin: 0.6em 0 1em 1.5em;
    padding-left: 1.4em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #8b5cf6; /* accent bullet color */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}

/* ===== COLLAPSIBLE SECTIONS ===== */
.mindmap details {
    /* FIX: Increased border width and used a darker color */
    border-left: 5px solid #7c3aed; 
    background: #ffffff;
    margin: 8px 0;
    /* FIX: Corrected typo "20x" to "20px" */
    padding: 9px 25px; 
    border-radius: 20px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.1);
    transition: all 0.3s ease;
    position: relative;
}

/* Subsection (nested details) */
.mindmap details > div > details {
    margin-left: -8px;
    /* FIX: Used a darker, more saturated color for the nested border */
    border-color: #9333ea; 
    background: #faf7ff;
}

/* Subtle hover feedback */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.18);
    background: linear-gradient(135deg, #ffffff, #f5f0ff);
}

/* ===== SUMMARY HEADERS ===== */
.mindmap summary {
    cursor: pointer;
    font-size: 1.1em;
    font-weight: 600;
    list-style: none;
    position: relative;
    /* FIX: Increased padding slightly to prevent text from touching the arrow icon */
    padding-left: 24px; 
    color: #4c1d95;
    outline: none;
}

/* Custom arrow icon */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

/* Rotated arrow when open */
.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Section title emphasis */
.mindmap summary strong {
    display: block;
    font-size: 1.25em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Open section highlighting */
.mindmap details[open] > summary {
    background: #f3e8ff;
    border-radius: 8px;
    padding: 6px 10px;
}

/* Smooth fade for expanded content */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* ===== DESCRIPTION BOXES ===== */
.mindmap .desc-box {
    background: #fdfcff;
    border: 2px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 6px 10px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.05);
    transition: background 0.3s ease;
}
.mindmap .desc-box:hover {
    background: #f8f4ff;
}

/* ===== ANIMATIONS ===== */
@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}

/* ===== BUTTONS ===== */
button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
button:hover {
    background-color: #6b21a8;
    transform: scale(1.05);
}

/* ===== FLOATING CONTROL PANEL ===== */
#level-controls {
    position: fixed;
    bottom: 30px;
    left: 85%;
    transform: translateX(-50%);
    background: rgba(255, 255, 255, 0.05);
    padding: 10px 16px;
    border-radius: 12px;
    box-shadow: 0 4px 12px rgba(0, 0, 0, 0.15);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move;
    display: flex;
    align-items: center;
    gap: 6px;
}

/* Buttons inside the panel */
#level-controls button {
    background-color: rgba(124, 58, 237, 0.85);
    color: white;
    border: none;
    padding: 8px 14px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.95);
    transform: scale(1.05);
}

/* Search input inside panel */
#level-controls input {
    border: 1px solid #d5c4ff;
    border-radius: 8px;
    padding: 7px 10px;
    font-size: 0.95em;
    outline: none;
    width: 150px;
    transition: border-color 0.2s ease;
}
#level-controls input:focus {
    border-color: #8b5cf6;
}

/* Search count text */
#searchCount {
    margin-left: 8px;
    font-style: italic;
    color: #4c1d95;
    font-size: 0.9em;
}

/* ===== SEARCH HIGHLIGHT ===== */
mark.search-highlight {
    background-color: #fff59d;
    color: #000;
    border-radius: 3px;
    padding: 1px 3px;
}



/* ===== CLICK-TO-REVEAL: Spoiler Blur Style ===== */
.mindmap q {
    cursor: pointer;
    color: transparent;
    /* Apply a text-shadow with the same color as the text to create the blur effect */
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease;
}

.mindmap q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* Style for the revealed text */
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}




/*for full control button*/
/* ===== CLICK-TO-REVEAL: Spoiler Blur Style (with Read Mode) ===== */

/* This rule applies the blur ONLY when the mindmap is NOT in read-mode. */
.mindmap:not(.read-mode) q {
    cursor: pointer;
    color: transparent;
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease, color 0.3s ease;
}

.mindmap:not(.read-mode) q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* This combined rule handles BOTH cases for revealing text:
   1. The entire mindmap is in read-mode.
   2. An individual <q> has been clicked (in quiz mode).
*/
.mindmap.read-mode q,
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}


</style>

</style>
</head>
<body>

<!-- Updated Controls -->
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="zoomIn()">+</button>
    <button onclick="zoomOut()">-</button>
    <button onclick="resetView()">=</button>
    <!-- NEW: READ MODE TOGGLE BUTTON -->
    <button onclick="toggleReadMode()">Q/R</button>
</div>

<div class="mindmap">
<div class="mindmap">
<details><summary><strong>AGA Clinical Practice Update on Management of Gastric Polyps: Expert Review</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Source: Clinical Gastroenterology and Hepatology 2026 (AGA Institute)</li>
<li style="margin-left: 0px;">Topic: Diagnosis and Management of Gastric Mucosal Polyps</li>
<li style="margin-left: 0px;">Author(s): Anna M. Buchner, Robert J. Huang, Gregory Y. Lauwers, Hashem B. El-Serag</li>
</ul>
<details><summary><strong>1. Overview and Scope</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">CPU provides framework for understanding natural history, epidemiology of gastric polyps</li>
<li style="margin-left: 0px;">Advises on: endoscopic detection, classification, resection, and surveillance</li>
<li style="margin-left: 0px;">Addresses sampling/surveillance of mucosal pathology giving rise to polyps (atrophy, pseudo-pyloric/intestinal metaplasia)</li>
<li style="margin-left: 0px;">Complements AGA documents on gastric intestinal metaplasia, atrophic gastritis, high-quality upper endoscopy, and gastric cancer screening</li>
</ul>
</div></details>
<details><summary><strong>2. Epidemiology, Risk Factors, and Natural History (BPA 1–3, 5–6)</strong></summary><div style="padding-left: 20px;">
<details><summary><strong>2.1 Prevalence and Distribution</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Gastric polyps frequently identified during upper endoscopy exams</li>
<li style="margin-left: 0px;">In Western countries: 70%–94% are FGPs or GHPs</li>
<li style="margin-left: 0px;">Multiple polyp types coexist in 2%–3% of patients</li>
<li style="margin-left: 0px;">Prevalence study (2007–2008): 6.35% of patients had gastric polyps</li>
<li style="margin-left: 20px;">77% FGPs, 17% GHPs, 0.69% GAs, 0.1% inflammatory fibroids</li>
<li style="margin-left: 0px;">Higher prevalence (2008–2013): 7.72% FGPs, 1.79% GHPs, 0.09% GAs, 0.06% type 1 G-NETs</li>
<li style="margin-left: 0px;">Trend shift: GHPs decreased from 65% to 15%; FGPs increased from 19% to 77% (2004–2013, Beijing study)</li>
<li style="margin-left: 0px;">Prevalence of GAs, GHPs, neuroendocrine lesions ↑ with age; FGPs ↓ after age 60</li>
<li style="margin-left: 0px;">Female predominance for FGPs; equal/slight female predominance for GAs and GHPs</li>
</ul>
</div></details>
<details><summary><strong>2.2 Fundic Gland Polyps (FGPs)</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Prevalence: 47%–77% of polyps</li>
<li style="margin-left: 0px;">Site: body; can be multiple; small, sessile, usually &lt;1 cm, glassy surface</li>
<li style="margin-left: 0px;">Associated with: PPI use, FAP, GAPPS</li>
<li style="margin-left: 0px;">Surrounding mucosa usually normal without inflammatory changes</li>
<li style="margin-left: 0px;">Dysplasia in up to 48% of FAP-associated FGPs; &lt;1% in sporadic lesions</li>
<li style="margin-left: 0px;">Gastric adenocarcinoma progression in up to 15% of FAP cases</li>
<li style="margin-left: 0px;">Risk factors for dysplasia: mucosal carpeting by polyps, size &gt;1 cm</li>
<li style="margin-left: 0px;">Risk inversely associated with gastric atrophy, H pylori infection, GIM</li>
<li style="margin-left: 0px;">Positive associations: GERD and PPI use</li>
</ul>
</div></details>
<details><summary><strong>2.3 Gastric Hyperplastic Polyps (GHPs)</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Prevalence: 17%–55% of polyps</li>
<li style="margin-left: 0px;">Common in regions with high H pylori prevalence</li>
<li style="margin-left: 0px;">Site: antrum &gt; body; single or multiple; sessile or pedunculated, &lt;20 mm</li>
<li style="margin-left: 0px;">Surface erosions may occur in larger polyps</li>
<li style="margin-left: 0px;">Associated with: chronic gastritis (H pylori-related, autoimmune)</li>
<li style="margin-left: 0px;">Dysplasia detected in ~4% of polyps</li>
<li style="margin-left: 0px;">Malignant transformation: 0.8%–10%</li>
<li style="margin-left: 0px;">Neoplastic polyps tend to be &gt;20 mm</li>
<li style="margin-left: 0px;">H pylori eradication leads to 59% reduction in GHP prevalence (95% CI, 43%–75%)</li>
<li style="margin-left: 0px;">Successful eradication: 79% reduction (95% CI, 72%–86%)</li>
</ul>
</div></details>
<details><summary><strong>2.4 Gastric Adenomas (GAs)</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Prevalence: 1%–10% of polyps</li>
<li style="margin-left: 0px;">Site: antrum &gt; body; usually single; flat or sessile, &lt;20 mm</li>
<li style="margin-left: 0px;">Associated with: chronic gastritis (H pylori-related, autoimmune gastritis)</li>
<li style="margin-left: 0px;">Subtypes: intestinal-type (56%), foveolar-type (41%)</li>
<li style="margin-left: 0px;">Progression risk: 3%–4% for low-grade lesions; 5%–30% for high-grade</li>
<li style="margin-left: 0px;">Risk ↑ with polyp size, particularly &gt;20 mm</li>
<li style="margin-left: 0px;">Foveolar-type GA in H pylori-naïve stomach: very low to nonexistent transformation risk (raspberry-like appearance)</li>
<li style="margin-left: 0px;">Surrounding gastric mucosa carries higher risk of malignant transformation</li>
</ul>
</div></details>
<details><summary><strong>2.5 Pyloric Gland Adenomas</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Prevalence: &lt;3% of polyps</li>
<li style="margin-left: 0px;">Site: body &gt; antrum; usually single; sessile, pedunculated, or masses; 1–10 cm</li>
<li style="margin-left: 0px;">Associated with: autoimmune gastritis; second most common polyp in FAP; also seen in Lynch syndrome, juvenile polyposis</li>
<li style="margin-left: 0px;">High-grade dysplasia in up to 42% of cases</li>
<li style="margin-left: 0px;">Progression: 12%–30% of cases</li>
<li style="margin-left: 0px;">Risk factors for high-grade dysplasia: larger polyp size, tubulo-villous architecture, autoimmune gastritis</li>
<li style="margin-left: 0px;">In Lynch syndrome: higher-grade associated with male sex</li>
</ul>
</div></details>
<details><summary><strong>2.6 Oxyntic Gland Adenomas</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Rare, slow-growing neoplasm</li>
<li style="margin-left: 0px;">Site: body; polypoid or raised flat; solitary; 2–20 mm, typically &lt;10 mm</li>
<li style="margin-left: 0px;">Unique: arises from oxyntic mucosa; multilineage phenotype (chief cells, parietal cells, mucous neck cells)</li>
<li style="margin-left: 0px;">Usually normal adjacent gastric mucosa</li>
<li style="margin-left: 0px;">Large polyps and cases with mucus neck cell differentiation likely to progress</li>
</ul>
</div></details>
<details><summary><strong>2.7 Hamartomatous Polyps</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Juvenile polyps: rare; body &gt; antrum; pedunculated or sessile; 2–20 mm</li>
<li style="margin-left: 0px;">Peutz-Jeghers polyps: rare; any site; polypoid, lobulated on short broad stalk; solitary or multiple; 1–3 cm</li>
<li style="margin-left: 0px;">Cowden syndrome-associated: rare; any site; small, sessile, polypoid; multiple</li>
<li style="margin-left: 0px;">Cronkite-Canada syndrome-associated: rare; any site; sessile or flat with diffuse mucosal thickening</li>
<li style="margin-left: 0px;">Progression: juvenile up to 14%; Peutz-Jeghers 2%–3%; Cowden low risk; Cronkite-Canada very rare</li>
</ul>
</div></details>
<details><summary><strong>2.8 Gastric Neuroendocrine Tumors (G-NETs)</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Uncommon; up to 2% of all gastric polyps</li>
<li style="margin-left: 0px;">Types:</li>
<li style="margin-left: 20px;">Type 1: body atrophy/GIM with ECL cell proliferation; &gt;70% of cases; multiple, ≤2 cm</li>
<li style="margin-left: 20px;">Type 2: hypertrophic with ECL hyperplasia; MEN-1 and gastrinoma; multiple, ≤1 cm</li>
<li style="margin-left: 20px;">Type 3: normal surrounding mucosa; solitary, &gt;2 cm; worst prognosis</li>
<li style="margin-left: 0px;">Most (&gt;70%) arise in setting of autoimmune gastritis (type 1)</li>
<li style="margin-left: 0px;">Limited metastasis for types 1 and 2; higher rate for type 3</li>
</ul>
</div></details>
<details><summary><strong>2.9 PPI Use and Gastric Polyps</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">PPI use associated with 1.5–2.5-fold ↑ risk of FGPs</li>
<li style="margin-left: 0px;">PPI use ≥12 months: up to 5-fold increase in FGP risk</li>
<li style="margin-left: 0px;">Meta-analysis (12 studies through 2016): significant association 1.43 (95% CI, 1.24–1.64) fixed-effects; 2.</li>
</ul>
</div></details>
</div></details>
<details><summary><strong>3. Endoscopic Detection and Characterization of Gastric Polyps (BPA 4, 7–8)</strong></summary><div style="padding-left: 20px;">
<details><summary><strong>3.1 Systematic Endoscopic Examination Requirements</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">BPA 4: systematic endoscopic examination of polyps and surrounding gastric mucosa essential for assessing underlying pathology (H pylori-related gastritis, autoimmune gastritis, GIM)</li>
<li style="margin-left: 0px;">Determines subsequent management: biopsies of polyps, surrounding mucosa, and polyp resection</li>
<li style="margin-left: 0px;">BPA 8: evaluation should include complete inspection with HD-WLE and enhanced imaging (virtual chromoendoscopy)</li>
<li style="margin-left: 0px;">Endoscopists must recognize and photo-document endoscopic features of polyps and surrounding mucosal abnormalities</li>
<li style="margin-left: 0px;">Entire gastric mucosa should be carefully inspected using HD-WLE with adequate stomach distension, clearance of mucus debris</li>
<li style="margin-left: 0px;">Photo documentation required for gastric landmarks, lesions, and mucosal alterations</li>
<li style="margin-left: 0px;">HD-WLE alone is suboptimal for diagnosing mucosal alterations (gastric atrophy, GIM) or distinguishing dysplastic/cancerous polyps</li>
<li style="margin-left: 0px;">Rate of neoplastic lesions missed on upper endoscopy resulting in cancer diagnosis within 3 years: 4.7% to 11.3%</li>
<li style="margin-left: 0px;">Subtle mucosal lesions surrounding GIM associated with interval development of early cancer</li>
</ul>
</div></details>
<details><summary><strong>3.2 Polyp Characteristics by Type (BPA 7)</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>GHPs</strong>: sessile or pedunculated, &lt;20 mm diameter, typically single polyp in antrum; can arise as multiple polyps anywhere in gastric mucosa</li>
<li style="margin-left: 0px;"><strong>FGPs</strong>: usually small, multiple, sessile; uniquely located in gastric body and fundus; in FAP setting can coalesce and become dysplastic</li>
<li style="margin-left: 0px;"><strong>Hamartomatous polyps</strong>: typically sessile, solitary, predominantly in gastric body; not easily distinguishable from GHPs</li>
<li style="margin-left: 0px;"><strong>GAs</strong>: typically single, flat, &lt;20 mm, occur in gastric antrum; larger sizes &gt;20 mm with villous histology have higher cancer risk</li>
<li style="margin-left: 0px;"><strong>G-NETs</strong>: small type 1 or type 2 sessile lesions associated with autoimmune gastritis or Zollinger-Ellison syndrome with MEN-1; can exist with/without central depression; occur in gastric body/fundus</li>
<li style="margin-left: 20px;">Type 3: ~15% of NETs; solitary, larger polyps up to 5 cm; not associated with hypergastrinemia; worst prognosis</li>
</ul>
</div></details>
<details><summary><strong>3.3 Image-Enhanced Endoscopy (IEE) Techniques</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Virtual chromoendoscopy with IEE includes: NBI, BLI, LCI with or without magnifying endoscopy</li>
<li style="margin-left: 0px;">Improves detection and characterization of dysplastic gastric lesions and abnormal gastric mucosa</li>
<li style="margin-left: 0px;">Enhances color contrast between dysoplastic areas and surrounding mucosa</li>
<li style="margin-left: 0px;">Enables clear visualization of surface structures and blood vessels during close-up observations</li>
<li style="margin-left: 0px;"><strong>LCI</strong>: highlights purple color of GIM, distinguishing from inflammatory gastric mucosa; aids identification of early dysplastic/neoplastic lesions adjacent to GIM</li>
</ul>
</div></details>
<details><summary><strong>3.4 NBI Classification System</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Validation study by Pimentel-Nunes et al proposed simplified classification:</li>
<li style="margin-left: 20px;"><strong>Pattern A</strong>: regular vessels with circular mucosa → normal histology (accuracy 83%; 95% CI, 75%–90%)</li>
<li style="margin-left: 20px;"><strong>Pattern B</strong>: tubulo-villous mucosa → linked to GIM (accuracy 84%; LR+, 4.75)</li>
<li style="margin-left: 20px;"><strong>Pattern C</strong>: irregular vessels and mucosa → associated with dysplasia (accuracy 95%; 95% CI, 90%–99%; LR+, 44.33)</li>
<li style="margin-left: 0px;">&quot;Light-blue crest&quot; sign: moderate reliability (k = 0.49) but specific (87%) for GIM</li>
<li style="margin-left: 0px;">Variable vascular density: best feature for identifying H pylori-related gastritis (accuracy 70%)</li>
</ul>
</div></details>
<details><summary><strong>3.5 Early Gastric Cancer Detection</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Endoscopic diagnostic criteria (vessel-plus-surface classification): irregular microvascular pattern and/or irregular microsurface pattern with demarcation line separating early cancerous lesion from normal mucosa</li>
<li style="margin-left: 0px;">Magnifying BLI and NBI: similar sensitivities for detecting demarcation line (96.1% vs 98.1%)</li>
<li style="margin-left: 0px;">Irregular microvessel patterns: sensitivities 95.1% (BLI) and 96.2% (NBI)</li>
<li style="margin-left: 0px;">Irregular microsurface patterns: 97.1% with BLI vs 78.8% with NBI</li>
</ul>
</div></details>
<details><summary><strong>3.6 Additional Endoscopic Classifications</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Kimura-Takemoto classification</strong>: for gastric atrophy (not routinely applied in US practice)</li>
<li style="margin-left: 0px;"><strong>EGGIM</strong> (endoscopic grading of GIM): for gastric intestinal metaplasia assessment</li>
<li style="margin-left: 0px;">Interobserver reliability of endoscopic findings: moderate overall; depends on years of experience and training</li>
<li style="margin-left: 0px;">Future implementation could help standardize findings, develop targeted biopsy guidance, optimize procedures</li>
</ul>
</div></details>
<details><summary><strong>3.7 Guidelines and Recommendations</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">AGA, American College of Gastroenterology, European organizations recommend routine use of IEE as guiding tool for assessing atrophic/metaplastic changes and targeting dysplastic lesions</li>
<li style="margin-left: 0px;">Computer-assisted AI systems introduced for early detection of dysplastic lesions</li>
<li style="margin-left: 0px;">IEE commonly used in Eastern countries; underutilized by US endoscopists</li>
<li style="margin-left: 0px;">Until US endoscopists acquire skills to distinguish mucosal abnormalities using IEE: meticulous evaluation and random/targeted biopsies of polyps and surrounding mucosa remain essential</li>
</ul>
</div></details>
</div></details>
<details><summary><strong>4. Endoscopic Management of Gastric Polyps and Surrounding Gastric Mucosa (BPA 9–11)</strong></summary><div style="padding-left: 20px;">
<details><summary><strong>4.1 Resection Techniques Overview</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">BPA 9: endoscopic resection includes traditional techniques (snare, biopsy forceps, mucosal resection) or ESD</li>
<li style="margin-left: 0px;">Goal: completely remove lesion while providing tissue for accurate pathological assessment of most advanced features</li>
<li style="margin-left: 0px;">Technique choice incorporates: presumed polyp pathology, size, location, endoscopist expertise</li>
</ul>
</div></details>
<details><summary><strong>4.2 Biopsy Forceps Polypectomy</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Little direct data on cold forceps for small gastric polyps ≤3 mm; supported by colon literature</li>
<li style="margin-left: 0px;">Large prospective study (colonic polyps ≤3 mm): cold forceps polypectomy (2.4-mm-diameter large forceps) noninferior to cold snare for complete resection; faster procedure</li>
<li style="margin-left: 0px;">Polyps ≥4 mm should NOT be resected using forceps technique</li>
</ul>
</div></details>
<details><summary><strong>4.3 Snare Polypectomy and EMR</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Prospective studies evaluated forceps vs EMR for larger polyps (≥5 mm): all 4 studies showed forceps cannot reliably establish underlying</li>
</ul>
</div></details>
<details><summary><strong>4.3 Snare Polypectomy and EMR (continued)</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">neoplasia in larger polyps</li>
<li style="margin-left: 0px;">For polyps 4–10 mm: cold snare or EMR are appropriate</li>
<li style="margin-left: 0px;">Taiwan study: cold snare noninferior to EMR regarding adverse events (most commonly bleeding) in gastric polypectomy</li>
<li style="margin-left: 0px;">Taiwanese study: cold snare safe and effective for removing FGPs 3–8 mm in size</li>
<li style="margin-left: 0px;">EMR adverse events: largest study shows bleeding rate ~7%, majority managed endoscopically; perforation rare</li>
</ul>
</div></details>
<details><summary><strong>4.4 Endoscopic Submucosal Dissection (ESD)</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Should be restricted to polyps where neoplasia is diagnosed or strongly suspected</li>
<li style="margin-left: 0px;">Single-center Korean study of 282 gastric adenomatous polyps removed by ESD:</li>
<li style="margin-left: 20px;">High complete resection rate (96%)</li>
<li style="margin-left: 20px;">Low bleeding rate (1.4%)</li>
<li style="margin-left: 20px;">No perforations</li>
<li style="margin-left: 0px;">Lesion size &gt;20 mm predictive of early gastric cancer</li>
<li style="margin-left: 0px;">Two reports: gastric ESD can be performed safely and efficiently in the West</li>
<li style="margin-left: 0px;">Both EMR and ESD allow for en bloc resection depending on polyp size/morphology; even &gt;20 mm pedunculated polyp can be resected en bloc by EMR</li>
<li style="margin-left: 0px;">Referral to endoscopist with advanced resection expertise advised if polyp size exceeds 20 mm</li>
</ul>
</div></details>
<details><summary><strong>4.5 Management Strategy for Newly Diagnosed Polyps</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">All newly detected solitary polyps should be resected at index endoscopy (diagnostic and therapeutic intent)</li>
<li style="margin-left: 0px;">For multiple gastric polyps: use knowledge of regional polyp epidemiology, clinical history, polyp characteristics to inform approach</li>
<li style="margin-left: 0px;">If all suspected to be FGPs: resect largest suspected FGP; other suspected FGPs can be resected if large (&gt;10 mm) or visually atypical</li>
<li style="margin-left: 0px;">If not all polyps believed to be FGPs:</li>
<li style="margin-left: 20px;">At minimum: resect largest suspected non-FGP polyp to establish histologic diagnosis and assess for deeper neoplasia</li>
<li style="margin-left: 20px;">If procedural factors allow: complete removal of all suspected non-FGP polyps may obviate need for second procedure</li>
<li style="margin-left: 20px;">Use separate specimen jars for each suspected polyp type</li>
</ul>
</div></details>
<details><summary><strong>4.6 Biopsy Sampling Protocols (BPA 11)</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Suspected abnormalities in surrounding mucosa (GIM or AG) should undergo targeted biopsies according to existing protocols</li>
<li style="margin-left: 0px;">If suspected non-FGP detected on index endoscopy: mucosal sampling using updated Sydney System or MAPPS II protocol</li>
<li style="margin-left: 0px;">If solitary gastric polyp observed: systematic mucosa sampling recommended</li>
<li style="margin-left: 0px;">Topographic pattern of inflammation, atrophy, GIM from protocols helps distinguish H pylori-related vs autoimmune gastritis</li>
<li style="margin-left: 0px;">Updated Sydney System: biopsies from five zones (antrum lesser/greater curves, incisura, body lesser/greater curves); biopsies placed in separate jars (antrum and body); targeted biopsies of visible lesions in separate jar</li>
</ul>
</div></details>
</div></details>
<details><summary><strong>5. Post-Endoscopic Treatment Management and Surveillance (BPA 12–14)</strong></summary><div style="padding-left: 20px;">
<details><summary><strong>5.1 Surveillance Framework Based on Polyp Type</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">BPA 12: surveillance plans formulated based on histopathological type of polyps and surrounding gastric mucosa</li>
<li style="margin-left: 0px;">Accurate histological classification crucial for determining therapeutic and surveillance strategies</li>
<li style="margin-left: 0px;">Comprehensive histological assessment of polyp and surrounding gastric mucosa needed to evaluate malignant progression risk</li>
<li style="margin-left: 0px;">Ethnic origin and family history of gastric cancer associated with risk but should not alter surveillance frequency (mediated by gastric mucosal status)</li>
<li style="margin-left: 0px;">Polyp size (irrespective of type) and presence of dysplasia guide management</li>
</ul>
</div></details>
<details><summary><strong>5.2 FGP Surveillance</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Non-syndromic FGPs devoid of dysplasia: surveillance not usually needed</li>
<li style="margin-left: 0px;">Syndromic patients with dysplastic FGP, large polyps (&gt;10 mm), or mucosal carpeting: watchful follow-up advised (associated with gastric cancer development)</li>
<li style="margin-left: 0px;">&gt;10 mm, no dysplasia: surveillance in 1 year; consider PPI discontinuation</li>
<li style="margin-left: 0px;">Mucosal carpeting (&gt;20 polyps): surveillance in 1 year; discontinue PPI and consider evaluation for familial polyposis syndrome</li>
<li style="margin-left: 0px;">With dysplasia: 6 months for high-grade, 1 year for low-grade; evaluate for familial polyposis syndrome</li>
</ul>
</div></details>
<details><summary><strong>5.3 GHP Surveillance</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">&lt;10 mm, no dysplasia: surveillance not clearly indicated if all polyps resected; ensure H pylori negativity</li>
<li style="margin-left: 0px;">If gastric premalignant conditions present: follow AGA advice</li>
<li style="margin-left: 0px;">&gt;10 mm, no dysplasia: endoscopic surveillance in 1 year</li>
<li style="margin-left: 0px;">With dysplasia: 6 months for high-grade, 1 year for low-grade</li>
</ul>
</div></details>
<details><summary><strong>5.4 Adenoma Surveillance (BPA 13)</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Includes intestinal-type, pyloric gland, and oxyntic gland adenomas</li>
<li style="margin-left: 0px;">Ensure complete removal of index adenoma; consider referral to endoscopist with advanced resection expertise</li>
<li style="margin-left: 0px;">High-grade dysplasia: initial follow-up at 6 months, then annually thereafter</li>
<li style="margin-left: 0px;">Low-grade dysplasia: initial follow-up at 12 months, then annually</li>
<li style="margin-left: 0px;">If polyp biopsied or resection incomplete: follow-up within 3 months for high-grade dysplasia, 6 months for low-grade dysplasia</li>
<li style="margin-left: 0px;">Ensure H pylori negativity; if gastric premalignant conditions present, follow AGA advice</li>
</ul>
</div></details>
<details><summary><strong>5.5 G-NET Surveillance</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Type I or II:</li>
<li style="margin-left: 20px;">If ≥2 cm: consider referral to oncologic center with expertise</li>
<li style="margin-left: 20px;">If &lt;2 cm: every 1–2 years</li>
<li style="margin-left: 0px;">If autoimmune gastritis present: follow existing AGA advice</li>
<li style="margin-left: 0px;">Type II: evaluation for source of inappropriate gastrin production</li>
<li style="margin-left: 0px;">Type III: referral to oncologic center with expertise</li>
</ul>
</div></details>
<details><summary><strong>5.6 Pyloric Gland and Oxyntic Gland Adenoma Management</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Same approaches as other adenomas recommended</li>
</ul>
</div></details>
<details><summary><strong>5.7 Tattooing Recommendations</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Routine tattooing not advised for most diagnostic or therapeutic gastric polypectomies</li>
<li style="margin-left: 0px;">Can be considered (optional) for: site of incompletely resected large polyps, suspected malignant polyps, when surgery or EMR/ESD follow-up planned</li>
</ul>
</div></details>
<details><summary><strong>5.8 Assessment of Surrounding Gastric Mucosa (BPA 14)</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Endoscopic surveillance advised when histopathology of adjacent mucosa confirms GIM and/or atrophic gastritis</li>
<li style="margin-left: 0px;">Patients with longstanding H pylori-related or autoimmune gastritis who developed mucosal atrophy, pseudo-pyloric metaplasia, or GIM have increased risk of gastric polyps</li>
<li style="margin-left: 0px;">Obtain biopsies from gastric antrum and corpus at minimum</li>
<li style="margin-left: 0px;">Successful H pylori eradication: leads to regression of hyperplastic polyps, improves AG, decreases gastric cancer risk</li>
<li style="margin-left: 0px;">Targeted biopsies every 3 years for: persistent H pylori infection, advanced AG with incomplete GIM detected, mild/focal GIM with family history of gastric cancer</li>
<li style="margin-left: 0px;">Duration of surveillance not yet determined</li>
<li style="margin-left: 0px;">Clinicians should assess multiple high-risk features and engage in shared decision-making</li>
</ul>
</div></details>
</div></details>
<details><summary><strong>6. Conclusion</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">CPU summarizes BPA statements for diagnosing and managing gastric polyps</li>
<li style="margin-left: 0px;">Gastric polyps are among most encountered lesions detected during upper endoscopy</li>
<li style="margin-left: 0px;">Proposed management includes: endoscopic characterization of polyps and adjacent mucosa using image-enhancement tools, followed by biopsy, resection, appropriate follow-up surveillance exams</li>
<li style="margin-left: 0px;">Systematic evaluation of polyps and surrounding mucosa essential for accurate diagnosis and management</li>
<li style="margin-left: 0px;">Image-enhanced endoscopy improves detection and characterization of dysplastic lesions and mucosal abnormalities</li>
<li style="margin-left: 0px;">Surveillance intervals based on polyp histology, dysplasia presence, and surrounding gastric mucosa status</li>
<li style="margin-left: 0px;">Management requires individualized approach considering polyp characteristics, patient factors, and available expertise</li>
</ul>
</div></details>
</div></details>
</div>
</div>

<br>
<br>
<br>
<br>
<br>


<script>
// --- State Management for Expansion Level ---
let currentLevel = 1; 
const maxLevel = 10;
const minLevel = 1;

// --- Core Function to Set Mindmap Expansion ---
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');
    allDetails.forEach(detail => detail.removeAttribute('open'));
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') {
                depth++;
            }
            parent = parent.parentElement;
        }
        if (depth < level) {
            detail.setAttribute('open', '');
        }
    });
}

// --- Control Functions ---
function zoomIn() {
    if (currentLevel < maxLevel) {
        currentLevel++;
        setMindmapLevel(currentLevel);
    }
}

function zoomOut() {
    if (currentLevel > minLevel) {
        currentLevel--;
        setMindmapLevel(currentLevel);
    }
}

function resetView() {
    currentLevel = minLevel;
    setMindmapLevel(currentLevel);
}


// --- NEW: Function to Toggle Read/Quiz Mode ---
function toggleReadMode() {
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.classList.toggle('read-mode');
    }
}

// --- Draggable Controls ---
function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;
    const onMouseDown = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };
    const elementDrag = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none";
        elmnt.style.bottom = "auto";
    };
    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };
    if (document.getElementById(elmnt.id)) {
        document.getElementById(elmnt.id).onmousedown = onMouseDown;
    } else {
        elmnt.onmousedown = onMouseDown;
    }
}




// --- Initial Setup ---
window.addEventListener('DOMContentLoaded', () => {
    // Set the initial mindmap view
    setMindmapLevel(currentLevel);

    // Get the draggable controls element
    const controls = document.getElementById('level-controls');
    if (controls) {
        dragElement(controls);
    }

    // --- CORRECTED & IMPROVED: Setup for Click-to-Reveal ---
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.addEventListener('click', function(event) {
            // Use .closest() to find the nearest parent <q> tag.
            // This is more robust than checking event.target.tagName.
            const quoteElement = event.target.closest('q');
            
            if (quoteElement) {
                // Add the 'is-revealed' class to show the text
                quoteElement.classList.add('is-revealed');
            }
        });
    }
});
</script>

</body>
</html>
